Valuation: Relay Therapeutics, Inc.

Market Cap 4.52B 3.96B 3.65B 3.38B 6.4B 431B 6.51B 43.64B 17.12B 212B 16.98B 16.61B 731B P/E 2026 *
-13.4x
P/E 2027 * -13.1x
Enterprise Value 4.23B 3.71B 3.42B 3.16B 5.99B 403B 6.09B 40.82B 16.01B 199B 15.88B 15.54B 684B EV / Sales 2026 *
337x
EV / Sales 2027 * 270x
Free-Float
93.64%
Yield 2026 *
-
Yield 2027 * -
1 day-3.59%
1 week+7.27%
Current month+6.92%
1 month+48.30%
3 months+33.90%
6 months+150.38%
Current year+136.47%
1 week 18.34
Extreme 18.345
20.79
1 month 14.2
Extreme 14.2
20.79
Current year 7.01
Extreme 7.01
20.79
1 year 3.02
Extreme 3.025
20.79
3 years 1.78
Extreme 1.775
20.79
5 years 1.78
Extreme 1.775
38.15
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 2017-02-28
Director of Finance/CFO 49 2018-03-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 2015-05-03
Director/Board Member 66 2016-06-30
Director/Board Member 52 2017-02-28
Date Insider Type Main position Quantity % Market Cap.
07-06Sell

Chief Executive Officer

-48,199 0.0252%
07-05Sell

Chief Technology Officer

-8,660 0.0045%
07-05Sell

Chief Financial Officer

-17,717 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
-3.59%+7.27%+436.33%+62.77% 4.52B
+0.58%+3.79%+4.16%+11.62% 50.44B
-2.22%-1.25%+385.40%+586.81% 40.63B
-0.54%+0.39%+25.57%-5.28% 34.88B
-1.36%+0.35%+17.88%+55.14% 33.67B
+1.21%-0.79%+4.46%+35.18% 26.29B
-1.81%-1.48% - - 17.11B
+0.51%-3.47%+63.97%+122.60% 15.29B
-9.37%-28.79%+37.45%+39.42% 10.62B
+0.23%-0.58%+13.76%+21.11% 13.74B
Average -1.64%-0.78%+109.89%+103.26% 24.72B
Weighted average by Cap. -0.93%+0.18%+91.35%+129.93%

Financials

2026 *2027 *
Net sales 12.54M 10.99M 10.13M 9.36M 17.74M 1.2B 18.04M 121M 47.46M 589M 47.07M 46.05M 2.03B 15.95M 13.98M 12.89M 11.91M 22.57M 1.52B 22.95M 154M 60.38M 749M 59.89M 58.59M 2.58B
Net income -291M -255M -235M -217M -412M -27.75B -419M -2.81B -1.1B -13.67B -1.09B -1.07B -47.03B -309M -271M -249M -231M -437M -29.46B -444M -2.98B -1.17B -14.51B -1.16B -1.13B -49.93B
Net Debt -292M -256M -236M -218M -413M -27.85B -420M -2.82B -1.11B -13.72B -1.1B -1.07B -47.21B -221M -194M -178M -165M -313M -21.06B -318M -2.13B -836M -10.38B -829M -811M -35.71B
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
193
Date Price Change Volume
26-07-10 US$20.01 -3.59% 3,186,888
26-07-09 US$20.75 +5.71% 4,433,384
26-07-08 US$19.63 -0.56% 4,312,268
26-07-07 US$19.74 +4.44% 5,145,109
26-07-06 US$18.90 +1.34% 3,147,259
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
20.75USD
Average target price
25.08USD
Spread / Average Target
+20.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLAY Stock